TCR peptide data

The Palo Alto company presented results of a physician-sponsored Phase I trial in 11 patients, showing that the TCR peptide engendered enhanced immune responses from regulatory T cells that release cytokines when they encounter abnormal T cells.

As reported at the meeting on Understanding and Treatment of Multiple Sclerosis in Cambridge, Mass., several patients have received boosters for more than three years. Patients also showed decreased immune responsiveness to myelin basic protein, which is implicated in the disease. ...